NASDAQ
6.18USD
+0.13 (+2.15%)
We have scored 5 news catalysts on Anteris Technologies Global Corp. (AVR) over the past 12 months. The biggest single-day move next to one of them came Jan 22, 2026, when AVR closed +8.4%: “Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock”. Coverage across the window leans positive (average ticker sentiment +0.68). Most of the impact sits in short squeeze potential and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
602.3M
P/E
—
EPS
—
Beta
0.73
52W range
3.3-11.06
Day range
6.05–6.25
Open
6.09
Prev close
6.05
Volume
1.4M
Avg volume
1.1M
Dividend
0.00
IPO
2024-12-13
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Anteris Technologies Global Corp. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for AVR: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering is the DurAVR transcatheter heart valve system, a pioneering transcatheter aortic valve engineered to treat aortic stenosis by precisely emulating the performance of a healthy human aortic valve. Beyond this, Anteris develops ADAPT anti-calcification tissue, a unique preparation that transforms xenograft tissue into robust bioscaffolds. These bioscaffolds are designed to simulate human tissue for various surgical repairs, notably in aortic valve replacement. Additionally, the ComASUR delivery system, a physician-designed balloon-expandable apparatus, features a reinforced, steerable catheter. This allows for highly accurate navigation through cardiac anatomy in a controlled manner, thereby mitigating potential damage to the aorta. Founded in 1999, Anteris Technologies Global Corp. operates out of Toowong, Australia.
